Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Surisham Dhillon

Newhall, CA Medical Doctor

NPI 1770652299 CMS profile 34671

23928 Lyons Ave Ste 204, Newhall, CA 91321

Open in the dashboard

General payments

$2,608

155 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$101,352 paid to institutions, not to them · program years 2019–2021

Through program year 2024, Surisham Dhillon of Newhall, CA is reported in the CMS Open Payments database as having received $2,608 across 155 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $101,352 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $30 1
2023 General $100 4
2022 General $669 31
2021 General $153 10
2020 General $367 19
2019 General $1,288 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Surisham Dhillon
  • California median
  • Middle half of California
  • National median

In program year 2025, general payments to Surisham Dhillon were reported at $0. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.

Show as a table
Year Surisham Dhillon California median Middle half National median
2019 $1,288 $161 $50–$652 $163
2020 $367 $114 $34–$392 $114
2021 $153 $137 $41–$509 $132
2022 $669 $152 $48–$573 $149
2023 $100 $162 $50–$581 $160
2024 $30 $162 $52–$583 $164
2025 $0 $172 $54–$610 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $558 28 payments
  2. Supernus Pharmaceuticals, Inc. $235 28 payments
  3. UCB, Inc. $192 10 payments
  4. Genzyme Corporation $158 12 payments
  5. Avanir Pharmaceuticals, Inc. $126 11 payments
  6. LivaNova USA, Inc. $116 6 payments
  7. Amgen Inc. $114 6 payments
  8. Genentech USA, Inc. $106 6 payments
  9. EMD Serono, Inc. $95 4 payments
  10. ASSERTIO THERAPEUTICS, Inc. $81 4 payments
  11. Other $827 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,608 155 payments
Products named General payments · program years 2019–2024
  1. QULIPTA $500 25 payments
  2. Briviact $192 10 payments
  3. OXTELLAR XR $150 18 payments
  4. NUEDEXTA $126 11 payments
  5. VNS Therapy $116 6 payments
  6. AIMOVIG $114 6 payments
  7. AUBAGIO $109 9 payments
  8. OCREVUS $106 6 payments
  9. UBRELVY $88 4 payments
  10. TROKENDI XR $86 10 payments
  11. Other $1,160 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record